AMG 357

Drug Profile

AMG 357

Alternative Names: AMG-357

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in New Zealand (PO, Capsule)
  • 01 May 2016 Amgen terminates phase I trial in Rheumatoid arthritis in USA (PO) (NCT02499315)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top